Drug Trial Radar · NCT07567833
Longitudinal Study of Retinal Function in Eyes Treated for Diabetic Macular Edema With Anti-VEGF Agents
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Jul 31, 2026
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Jaeb Center for Health ResearchAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Eye Institute (NEI)
- First posted
- May 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A considerable hurdle to the development of novel, more effective therapies for diabetic retinal disease is the limited number of primary endpoints available for use in regulatory trials. Current endpoints necessitate long trial durations and a greater number of participants to show efficacy. Thus, a better understanding of the structural and functional changes in the retina occurring in people with diabetes is essential for developing primary endpoints and validating surrogate and clinical endpoints.
Conditions
- Diabetic Retinal Disease
Interventions
Anti-Vascular Endothelial Growth FactorDrug
All study eyes will receive an injection of anti-VEGF at baseline, 4, and 8 weeks. The participant will then be assessed for treatment every 8 weeks. At and after the 16-week visit, an injection will only be given if the eye has center-involved DME or visual acuity worse than 20/20 (presumed to be due to DME). Otherwise, an injection will not be given. The follow-up interval remains 8 weeks regardless of whether an injection is given or deferred. However, if an injection is deferred and the participant experiences vision issues or other symptoms, they may return for evaluation prior to 8 weeks (e.g., in 4 weeks) and can receive an injection (provided it has been at least 21 days since the last injection).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in multifocal pupillographic objective perimetry (mfPOP) response delaysTime frame: Baseline to 1 year
- Change in area under the log contrast sensitivity function (AULCSF)Time frame: Baseline to 1 year
- Change in electroretinography parameterTime frame: Baseline to 1 year
- Change in reading performanceTime frame: Baseline to 1 year
- Change in visual field functionTime frame: Baseline to 1 year
- Change in diabetic retinopathy severityTime frame: Baseline to 1 year
- Change in retinal vascular pathologyTime frame: Baseline to 1 year
- Change in retinal structureTime frame: Baseline to 1 year
- Change in retinal microvascular parameterTime frame: Baseline to 1 year
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Retina Consultants of Southern California
Huntington Beach, California · Recruiting
Southeast Retina Center, P.C.
Augusta, Georgia · Recruiting
Boston Medical Center Corporation
Boston, Massachusetts · Recruiting
Henry Ford Health System
Detroit, Michigan · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
Retina-Vitreous Consultants, Inc.
Monroeville, Pennsylvania · Recruiting
Pittsburgh Clinical Trial Consortium
Sewickley, Pennsylvania · Recruiting
Retina Consultants of Texas
Beaumont, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.